Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in CRSP.
← Back to Free Index

CRSP

Analysis as of: 2026-05-21
CRISPR Therapeutics AG
CRISPR Therapeutics develops gene-edited medicines and cell therapies, including the approved hemoglobinopathy therapy CASGEVY and a broader pipeline in cardiovascular, autoimmune, oncology, and regenerative medicine.
biotech healthcare
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

First approval won; platform rerating still earned
The company has already crossed the hardest credibility hurdle with an approved CRISPR therapy. The next five years depend less on scientific brand and more on whether at least one owned franchise proves scalable economics beyond the Vertex-led asset.

Analysis

Thesis
CRISPR Therapeutics has already cleared the credibility hurdle with the first approved CRISPR therapy; the five-year upside now comes from turning that proof point into a second real franchise, most plausibly liver editing or zugo-cel, while using its balance sheet and manufacturing know-how to keep more downstream economics.
Last Economy Alignment
Low software commoditization exposure helps because value sits in regulated therapies, clinical data, IP, and GMP execution rather than software seats. AI should improve discovery and development throughput, but biology, regulation, and manufacturing still cap how fast value converts.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.9x (from 5 most recent analyses)
Reasoning
A rerating does not require every pipeline program to work. It requires CASGEVY to become a durable economic stream, at least one owned franchise to show clinically credible and scalable economics, and management to preserve enough ownership that success accrues to shareholders rather than mostly to partners. If that happens, the company can move from proof-of-science optionality to a de-risked multi-franchise gene-editing story.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The central risk is proof conversion beyond CASGEVY. CRISPR Therapeutics has real scientific credibility, manufacturing assets and ample liquidity, but the 2031 upside still depends on turning early owned programs into clinically persuasive, regulatorily navigable and economically attractive products while retaining enough downstream ownership to matter.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.44
They control hard-to-copy pieces of gene editing: clinical know-how, regulatory trust and manufacturing for future cell therapies, so AI helps them design faster without making the product free. The risk is that biology and regulation stay slower than software, and the first product's economics are still heavily shaped by a partner.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$82.82
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case